Ubs Group Ag Rigel Pharmaceuticals Inc Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024
BUY
$1.12 - $1.57 $31,137 - $43,647
27,801 Added 18.37%
179,164 $265,000
Q4 2023

Feb 09, 2024
BUY
$0.72 - $1.56 $52,697 - $114,177
73,191 Added 93.63%
151,363 $219,000
Q3 2023

Nov 09, 2023
SELL
$1.07 - $1.39 $38,563 - $50,096
-36,041 Reduced 31.56%
78,172 $84,000
Q2 2023

Aug 11, 2023
BUY
$1.12 - $1.82 $47,221 - $76,734
42,162 Added 58.52%
114,213 $147,000
Q1 2023

May 12, 2023
BUY
$1.25 - $2.0 $61,267 - $98,028
49,014 Added 212.76%
72,051 $95,000
Q4 2022

Feb 08, 2023
BUY
$0.67 - $11.9 $15,434 - $274,140
23,037 New
23,037 $34,000
Q2 2022

Aug 10, 2022
BUY
$0.67 - $3.19 $196,848 - $937,231
293,803 Added 98.91%
590,858 $668,000
Q1 2022

May 16, 2022
SELL
$2.22 - $3.45 $275,124 - $427,558
-123,930 Reduced 29.44%
297,055 $888,000
Q4 2021

Feb 14, 2022
BUY
$2.36 - $3.57 $956,161 - $1.45 Million
405,153 Added 2559.08%
420,985 $1.12 Million
Q3 2021

Nov 15, 2021
SELL
$3.5 - $4.5 $97,954 - $125,941
-27,987 Reduced 63.87%
15,832 $57,000
Q2 2021

Aug 13, 2021
SELL
$3.09 - $4.54 $837,173 - $1.23 Million
-270,930 Reduced 86.08%
43,819 $191,000
Q1 2021

May 12, 2021
BUY
$3.35 - $4.93 $1.05 Million - $1.55 Million
314,749 New
314,749 $1.08 Million
Q3 2020

Nov 12, 2020
SELL
$1.78 - $4.13 $62,047 - $143,963
-34,858 Closed
0 $0
Q2 2020

Jul 31, 2020
SELL
$1.41 - $2.05 $62,530 - $90,913
-44,348 Reduced 55.99%
34,858 $64,000
Q1 2020

May 01, 2020
SELL
$1.27 - $3.0 $163,363 - $385,899
-128,633 Reduced 61.89%
79,206 $124,000
Q4 2019

Feb 14, 2020
BUY
$1.6 - $2.43 $142,246 - $216,036
88,904 Added 74.75%
207,839 $445,000
Q3 2019

Nov 14, 2019
BUY
$1.63 - $2.62 $25,172 - $40,460
15,443 Added 14.92%
118,935 $222,000
Q2 2019

Aug 14, 2019
BUY
$2.02 - $2.61 $88,490 - $114,336
43,807 Added 73.4%
103,492 $270,000
Q1 2019

May 14, 2019
SELL
$2.0 - $2.65 $1.27 Million - $1.69 Million
-636,426 Reduced 91.43%
59,685 $153,000
Q4 2018

Feb 14, 2019
BUY
$2.08 - $3.36 $1.44 Million - $2.32 Million
690,511 Added 12330.55%
696,111 $1.6 Million
Q3 2018

Nov 14, 2018
SELL
$2.6 - $3.59 $31,327 - $43,255
-12,049 Reduced 68.27%
5,600 $18,000
Q2 2018

Aug 14, 2018
SELL
$2.83 - $4.11 $1.15 Million - $1.67 Million
-405,765 Reduced 95.83%
17,649 $50,000
Q1 2018

May 15, 2018
BUY
$3.54 - $4.54 $774,792 - $993,660
218,868 Added 107.0%
423,414 $1.5 Million
Q4 2017

Feb 14, 2018
BUY
$3.23 - $4.3 $624,765 - $831,731
193,426 Added 1739.44%
204,546 $794,000
Q3 2017

Nov 14, 2017
SELL
$2.18 - $2.57 $196,923 - $232,153
-90,332 Reduced 89.04%
11,120 $28,000
Q2 2017

Aug 14, 2017
BUY
N/A
95,397 Added 1575.51%
101,452 $277,000
Q1 2017

Nov 14, 2017
BUY
N/A
6,055
6,055 $20,000

Others Institutions Holding RIGL

# of Institutions
8
Shares Held
334K
Call Options Held
0
Put Options Held
0
View Full List

About RIGEL PHARMACEUTICALS INC

RIGL Quotes by TradingView
  • Ticker RIGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 172,836,000
  • Market Cap $2.96B
  • Description
  • Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...
More about RIGL
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email